- PR Newswire•5 months ago
DENVER, July 13, 2016 /PRNewswire/ -- Analytica (ASX: ALT) today announced that the U.S. Food and Drug Administration (FDA) has approved the PeriCoach® at-home pelvic floor trainer device and smartphone app as an over-the-counter (OTC) treatment for treatment of mild, moderate and stress urinary incontinence (UI) and urge incontinence. A strong pelvic floor is also associated with improved sexual function and satisfaction.
We're sorry this is all we were able to find about this topic.
ALT.AX : Summary for ANALYTICA FPO - Yahoo Finance
Analytica Ltd. (ALT.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||0.01 - 0.01|
|52 Week Range||0.00 - 0.01|
|PE Ratio (TTM)||-2.33|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|